Our target list for the US

Ranked accounts

This is the value we can capture now, and how to target them. Exposure is total pain carried: trials run times their average pain. Mean pain is whose mix sits in the hardest cells. Novartis tops both; below it, they diverge.

454,031registered trials
161,954with a US site
52,660pharma-run, in scope
750sponsors ranked (≥ 8 trials)
exposure = US industry trials × mean pain of their trial mixA big portfolio in easy cells and a small one in hard cells are different kinds of account, so both factors are shown in the table.
How to read thisExposure ranks who the pain lands on, not who is likeliest to buy. High on both factors earns a concentrated tag. Contract research organizations are not shown; the registry does not record them reliably. Methodology.

Click any column to sort, and any sponsor to see where to enter their portfolio first.

Show
1–25 of 750 sponsors

Evidence per account

Terminated and withdrawn US trials behind each ranking, linked to the registry.

1. Novartisn = 257terminated
2. Pfizern = 339terminated
3. Eli Lilly and Companyn = 119terminated
4. GlaxoSmithKlinen = 136terminated
5. AstraZenecan = 99terminated
6. Hoffmann-La Rochen = 106terminated
7. Bristol-Myers Squibbn = 129terminated
8. Sanofin = 106terminated
9. Amgenn = 94terminated
10. Merck Sharp & Dohme LLCn = 39terminated
11. Janssen Research & Development, LLCn = 66terminated
12. AbbVien = 80terminated
13. Boehringer Ingelheimn = 56terminated
14. Gilead Sciencesn = 102terminated
15. Bayern = 57terminated